Corcept Therapeutics (CORT)

Executive Summary

Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on selective cortisol modulators, with a strong foundation in its FDA-approved product Korlym (mifepristone) for Cushing's syndrome. The company has built a robust pipeline centered on relacorilant, a next-generation selective glucocorticoid receptor modulator that has demonstrated positive Phase 3 results in hypercortisolism and is advancing toward regulatory submission. Relacorilant's potential extends beyond Cushing's into oncology, particularly in adrenocortical carcinoma and prostate cancer, while the company continues to explore its proprietary cortisol modulation platform across multiple indications. With a market capitalization of approximately $4 billion, Corcept is well-positioned to leverage its commercial expertise and pipeline momentum, though it faces competitive pressures from other therapies targeting similar pathways. The near-term focus remains on the regulatory path for relacorilant in Cushing's syndrome and expanding its oncology footprint.

Upcoming Catalysts (preview)

• H2 2026FDA Decision on Relacorilant for Cushing's Syndrome80% success
• 2026Phase 3 Data for Relacorilant in Adrenocortical Carcinoma60% success
• H2 2026Phase 1/2 Update for Relacorilant + Enzalutamide in Prostate Cancer50% success